Litcius/Paper detail

Dysregulated miRNAs as Biomarkers and Therapeutical Targets in Neurodegenerative Diseases

Giulia Gentile, Giovanna Morello, Valentina La Cognata, Maria Guarnaccia, F. L. Conforti, Sebastiano Cavallaro

2022Journal of Personalized Medicine62 citationsDOIOpen Access PDF

Abstract

Alzheimer's disease (AD), Parkinson's disease (PD), and Amyotrophic Lateral Sclerosis (ALS) are representative neurodegenerative diseases (NDs) characterized by degeneration of selective neurons, as well as the lack of effective biomarkers and therapeutic treatments. In the last decade, microRNAs (miRNAs) have gained considerable interest in diagnostics and therapy of NDs, owing to their aberrant expression and their ability to target multiple molecules and pathways. Here, we provide an overview of dysregulated miRNAs in fluids (blood or cerebrospinal fluid) and nervous tissue of AD, PD, and ALS patients. By emphasizing those that are commonly dysregulated in these NDs, we highlight their potential role as biomarkers or therapeutical targets and describe the use of antisense oligonucleotides as miRNA therapies.

Topics & Concepts

microRNAMedicineBioinformaticsComputational biologyBiomarkerNeuroscienceBiologyGeneticsGeneNuclear Receptors and SignalingMicroRNA in disease regulationGDF15 and Related Biomarkers
Dysregulated miRNAs as Biomarkers and Therapeutical Targets in Neurodegenerative Diseases | Litcius